登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Efficacy and Safety of CD19/CD20 CAR/TRuC-T in Relapsed/Refractory B-Cell Lymphoma
ClinicalTrials.gov 上登记的一项淋巴瘤开放试验,由深圳大学总医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07508605,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 8
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(8 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Histologically confirmed relapsed/refractory B-cell lymphoma according to the 2020 World Health Organization (WHO) classification;
入选标准第 2 条
CD20 expression on tumor cells confirmed by flow cytometry and/or immunohistochemistry;
入选标准第 5 条
New York Heart Association (NYHA) Class III or IV heart failure, or left ventricular ejection fraction (LVEF) <50% on echocardiography;
入选标准第 16 条
No antibody-based therapy within 2 weeks prior to cell therapy. Exclusion Criteria
入选标准第 12 条
ECOG performance status of 0-2;
入选标准第 3 条
Abnormal complete blood count meeting any of the following: WBC ≤1 × 10⁹/L, ANC ≤0.5 × 10⁹/L, ALC ≤0.5 × 10⁹/L, or PLT ≤25 × 10⁹/L;
入选标准第 14 条
Laboratory abnormalities including, but not limited to, any of the following: total serum bilirubin ≥1.5 mg/dL; ALT or AST >2.5 times the upper limit of normal; serum creatinine ≥2.0 mg/dL;
入选标准第 15 条
At least one measurable and evaluable lesion according to RECIST 1.1;
入选标准第 10 条
currently pregnant or breastfeeding;
入选标准第 29 条
planning to become pregnant during the study period; or
入选标准第 30 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:试验排除的其他疾病。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07508605,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Aged 18 to 75 years, regardless of sex; Histologically confirmed relapsed/refractory B-cell lymphoma according to the 2020 World Health Organization (WHO) classification; ECOG performance status of 0-2; Expected survival of at least 3 months; CD20 expression on tumor cells confirmed by flow cytometry and/or immunohistochemistry; Patients who are resistant/refractory to CD19 CAR-T cell therapy or have low CD19 expression; No severe cardiac, pulmonary, hepatic, or renal disease; Able to understand and willing to sign the informed consent form for this study; No contraindications to peripheral blood mononuclear cell collection/apheresis; At least one measurable and evaluable lesion according to RECIST 1.1; Must have previously received standard first-line and second-line therapy; No antibody-based therapy within 2 weeks prior to cell therapy. Exclusion Criteria History of allergy to any component of the cell product; Abnormal complete blood count meeting any of the following: WBC ≤1 × 10⁹/L, ANC ≤0.5 × 10⁹/L, ALC ≤0.5 × 10⁹/L, or PLT ≤25 × 10⁹/L; Laboratory abnormalities including, but not limited to, any of the following: total serum bilirubin ≥1.5 mg/dL; ALT or AST >2.5 times the upper limit of normal; serum creatinine ≥2.0 mg/dL; New York Heart Association (NYHA) Class III or IV heart failure, or left ventricular ejection fraction (LVEF) <50% on echocardiography; Abnormal pulmonary function, with oxygen saturation <92% on room air; History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant severe cardiac disease within 12 months prior to enrollment; Grade 3 hypertension with poor blood pressure control despite medication; History of craniocerebral trauma, disturbance of consciousness, epilepsy, severe cerebral ischemia, or cerebral hemorrhagic disease; Presence of autoimmune disease, immunodeficiency, or other conditions requiring immunosuppressive therapy; Presence of uncontrolled active infection; Prior treatment with any CAR-T cell product or other genetically modified T-cell therapy; Receipt of a live vaccine within 4 weeks prior to enrollment; Positive for HIV, HBV, HCV, or TPPA/RPR, or HBV carrier status; History of alcohol abuse, drug abuse, or psychiatric illness; Participation in any other clinical study within 3 months prior to enrollment in this study; Female subjects meeting any of the following conditions: currently pregnant or breastfeeding; planning to become pregnant during the study period; or of childbearing potential and unwilling or unable to use effective contraception; Any other condition that, in the investigator's judgment, makes the subject unsuitable for participation in this study.排除标准:Exclusion Criteria:
引自 ClinicalTrials.gov, NCT07508605, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07508605,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。